|Mr. Michael A. Sherman M.B.A.||CEO, Pres & Director||1.11M||N/A||1966|
|Mr. Michael T. Andriole M.B.A.||Chief Bus. Officer, Sec. & CFO||657.35k||N/A||1973|
|Dr. Allen S. Melemed M.B.A., M.D.||Chief Medical Officer||508.92k||N/A||N/A|
|Mr. David Jakeman CPA||Exec. Director of Fin. & Accounting and Principal Accounting Officer||N/A||N/A||1978|
|Dr. Roy W. Ware||Chief Manufacturing & Technology Officer||N/A||N/A||N/A|
|Dr. Randall Lanier||Chief Science Officer||N/A||N/A||N/A|
|Ms. Michelle LaSpaluto||VP of Strategic Planning & Investor Relations||N/A||N/A||N/A|
|Dr. Michael A. Alrutz||Sr. VP, Gen. Counsel & Corp. Sec.||N/A||N/A||1970|
|Dr. Joshua E. Allen||Chief Technology Officer of Imipridones||N/A||N/A||N/A|
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Chimerix, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 8; Compensation: 8.